call +44 (0) 20 7060 7474
or email us
Search Results for
"Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report"
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
previous
Title  | Date  | Price | Relevance  |
|---|---|---|---|
| Competitive Outlook on Lung Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning Product Code: BSK00075 | Aug 2009 | £2,240.00 | 100 % |
| Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies Product Code: RBI00199 | Feb 2007 | £1,730.00 | 54 % |
| Cancer Drug Resistance 2008 Product Code: BPR00004 | Sep 2008 | £1,675.00 | 54 % |
| Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements Product Code: DAT11461 | Apr 2008 | £6,885.00 | 54 % |
| Cancer Drug Discoveries: Prostate Cancer Product Code: ESP00387 | May 2007 | £795.00 | 54 % |
| Targeted Therapeutics in Non-Small Cell Lung Cancer Product Code: BSK00011 | Apr 2007 | £1,425.00 | 54 % |
| Cancer Vaccine Developments to 2013 Product Code: ESP00119 | Sep 2007 | £1,296.00 | 54 % |
| Cancer Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Product Code: LSA10502 | Sep 2009 | £920.00 | 54 % |
| Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities Product Code: SPE00010 | Apr 2006 | £1,900.00 | 45 % |
| Protein Kinase Therapeutics in Oncology Where to Commercialize? Product Code: BSK00076 | Oct 2009 | £2,215.00 | 45 % |
| The Market for Bioengineered Protein Drugs Product Code: BCC00094 | Jan 2007 | £2,915.00 | 45 % |
| The Executive Guide to Molecular Imaging Product Code: ESP00322 | Jul 2007 | £595.00 | 45 % |
| Therapeutic Peptides in Oncology Favorable Conditions But Where to Commercialize? Product Code: BSK00073 | May 2009 | £3,235.00 | 45 % |